Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.

This document summarises the Life Saving Drugs Program Expert Panel's consideration of the application from Alexion Pharmaceuticals Australasia Pty Ltd to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of perinatal- and infantile-onset hypophosphatasia (HPP).

The document contains:

  • Overview
  • Background
  • PBAC Consideration
  • Consumer Input
  • LSDP Expert Panel Consideration
    • Funding Criteria
    • Pricing Issues
  • Treatment Guidelines
    • Management of Uncertainties
  • Context
  • Sponsor’s Comment

Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022

About this resource

Publication date:
Publication type:
Report
Audience:
General public
Language:
English

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.